Neurolief Announces Positive Results From RIME Clinical Study of Its Brain Neuromodulation System for Treating Acute Migraine

TAMPA, Fla. & NETANYA, Israel--(BUSINESS WIRE)--Neurolief, a neurotechnology innovator, today announces findings of the RIME US pivotal trial that demonstrate the safety and efficacy of the Relivion®, a novel external brain neuromodulation system for self-administered treatment of migraine. The study met all its endpoints with statistical significance. “The results of this study are extremely promising for those seeking an effective, non-invasive, drug-free therapy for migraine,” said Stewart J

Click to view original post